Biotech · Private company
EirGenix, Inc.
Track this companyFree. Adds EirGenix, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials20 recruiting or active
Pipeline programs4From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline4
- EG12014Phase 3 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- EG1206APhase 3 · Early Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- HerceptinPhase 3 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- PerjetaPhase 3 · Early Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials2
- Efficacy and Safety Study of EG1206A (EirGenix' Pertuzumab) Compared With EU-sourced Perjeta® (Pertuzumab) in Patients With HER2-positive Hormone Receptor Negative Early Breast Cancer.PHASE3 · WITHDRAWN · started May 1, 2025ClinicalTrials.gov NCT06884254 · fetched Nov 12, 2026
- Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast CancerPHASE3 · COMPLETED · started Oct 16, 2018ClinicalTrials.gov NCT03433313 · fetched Nov 12, 2026